Outcome of board meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd reported FY2026 revenue of Rs. 9,274 Lakhs (vs Rs. 64.02 Lakhs in FY2025, though prior year appears incomplete). Net profit after tax turned positive at Rs. 495.98 Lakhs compared to a loss of Rs. 108.56 Lakhs in the prior year. EPS improved to Rs. 2.09 from Rs. (0.99). The company applied Ind AS 116 (Leases) retroactively, resulting in restated figures including Rs. 3.41 Lakhs additional depreciation, Rs. 1.66 Lakhs finance costs, and Rs. 4.32 Lakhs rent reversal. Trade receivables surged to Rs. 7,077.60 Lakhs from Rs. 60.05 Lakhs. Auditors issued an unmodified (clean) opinion. The company also transitioned to the new concessional tax regime under Section 115BAA of the Income-tax Act, 1961.
Strong turnaround from loss to profit year-on-year. However, the massive jump in trade receivables and negative operating cash flow of Rs. 947.43 Lakhs warrant scrutiny - investors should monitor collection cycles and cash generation going forward.